Clinical trial NCT00373217 (phase 2, status: terminated)
Conditions: fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    slow enrollment rate.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer

               -  Stage III or IV disease

          -  HLA-A1, -A2, and/or -A3 positive

          -  Must have at least 1 undissected axillary or inguinal lymph node basin

          -  No recurrent disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Hemoglobin ≥ 8.0 g/dL

          -  WBC > 3,000/mm^3

          -  Absolute neutrophil count > 1,500/mm^3

          -  Hemoglobin A1c < 7%

          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)

          -  Bilirubin ≤ 2.5 times ULN

          -  Creatinine ≤ 1.5 times ULN

          -  HIV negative

          -  Hepatitis C negative

          -  No known or suspected allergies to any component of the study vaccine

          -  No other concurrent malignancy (except for nonmelanoma skin cancer) unless the patient
             was curatively treated and has been disease free for ≥ 5 years

          -  No active serious infection

          -  No autoimmune disorder with visceral involvement

          -  No prior or active autoimmune disorders requiring cytotoxic or immunosuppressive
             therapy

               -  The following immunologic conditions are allowed:

                    -  Laboratory evidence of autoimmune disease (e.g., positive antinuclear
                       antibody titer) without symptoms

                    -  Clinical evidence of vitiligo

                    -  Other forms of depigmenting illness

                    -  Mild arthritis requiring NSAIDs

          -  No New York Heart Association class III or IV heart disease

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No medical contraindication or potential problem that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

          -  At least 2 weeks since prior and no other concurrent chemotherapy, radiotherapy, or
             immunotherapy (e.g., interferons, tumor necrosis factor, interleukins, or monoclonal
             antibodies)

          -  More than 4 weeks since prior and no other concurrent investigational agents

          -  More than 4 weeks since prior and no concurrent allergy desensitization injections

          -  More than 4 weeks since prior and no concurrent oral or parenteral systemic
             corticosteroids

          -  No prior or concurrent inhaled corticosteroids (e.g., fluticasone and salmetrol,
             fluticasone, or triamcinolone acetonide)

               -  Prior or concurrent topical corticosteroids allowed

          -  No prior vaccination with MAGE-A1:161-169, FBP:1901-199, Her-2/neu:369-377,
             MAGE-A1:96-104, or Her-2/neu:754-762

          -  More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa,
             darbepoetin alfa, or pegfilgrastim)

          -  No concurrent treatment for recurrent disease

          -  No concurrent nitrosoureas

          -  No concurrent illegal drug use

          -  Concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, and chronic
             medications, unless excluded, are allowed

          -  Short-term therapy for acute conditions not specifically related to ovarian cancer is
             allowed